The interstitial cystitis data base study: Concepts and preliminary baseline descriptive statistics

Simon, L; Landis, J. Richard; Erickson, Deborah; Nyberg, Leroy M.

doi:10.1016/s0090-4295(99)80334-3

Cited by 236 publications

(140 citation statements)

References 11 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Despite these limitations, each group had reductions in urinary frequency, increases in voided volumes and reductions in incontinent episodes. The IC database multicentre study found that incontinence was common in those with IC, particularly when the IC symptoms were more severe [11]. This was also the case in the present study, and although patients did not have neuromodulation because of complaints of incontinence, there was an improvement in this outcome during the follow-up.…”

Section: Discussionsupporting

confidence: 82%

A prospective, single‐blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis

2007

View full text Add to dashboard Cite

generator and patients were followed at 1, 3 and 6 months. RESULTSThe time required to place a sacral lead was 27.4 min, and a pudendal lead 19.6 min ( P = 0.039). Of the 22 patients, 17 (77%) responded and had a permanent implant placed. PNS was chosen as the better lead in 77% and SNS in 24%. The order in which the lead was stimulated had no effect on the final lead implanted and there was no 'carry-over' effect. The overall reduction in symptoms was 59% for PNS and 44% for SNS ( P = 0.05). At 6 months after implantation, voids improved by 41% (PNS) and 33% (SNS), and mean voided volume increased 95% and 21%, respectively; validated IC questionnaires improved markedly and complications were minimal. CONCLUSIONSThis is the first 'blinded' study of SNS vs PNS for IC. A pudendal lead was implanted successfully in all patients, and most chose PNS as better than SNS; the improvement was sustained over time.

show abstract

Section: Discussionsupporting

confidence: 82%

A prospective, single‐blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis

2007

View full text Add to dashboard Cite

show abstract

“…Consequently, we compared them by 97 variables clustered in the following sets: demographics (N=9); symptoms at onset, worst, and at present (17), sufficient medical records (3), findings at first medical encounter after symptom onset (14), findings at subsequent evaluations of their bladder disease (29), ICspecific therapy initially and ever (14), and medical history (11). Because of the large number of comparisons, we used a p-value of .01 to identify those with possibly significant differences.…”

Section: Resultsmentioning

confidence: 99%

“…The primary reason for this apparent misclassification was the ICS restriction to suprapubic pain. Others have noted lower abdominal or suprapubic pain to be present in the majority of IC/PBS patients; however, one quarter to one half do not report such pain but do report pain in other parts of the pelvis (14)(15)(16) . Indeed, in the ICS document itself, there is reason to believe that the authors intended at least retropubic pain to be additionally included as a symptom of IC/PBS.…”

Section: Discussionmentioning

confidence: 99%

“…Because a number of investigators have described the pain of IC/PBS in pelvic locations other than suprapubic or infrapubic (14)(15)(16) , one can make a case that any pelvic pain should be incorporated into the definition of IC/PBS. Consequently, if one were to insert "pelvic pain", which in our study would include suprapubic, infrapubic, genital, rectal or urethral, then all 138 (100%) of our participants would meet this case definition.…”

Section: Variations Of the Ics Definitionmentioning

confidence: 99%

See 1 more Smart Citation

Using the International Continence Society’s definition of painful bladder syndrome

Warren

Meyer

Greenberg

et al. 2006

Urology

View full text Add to dashboard Cite

Objectives-The case definition of interstitial cystitis (IC) is in flux. The International Continence Society (ICS) suggested a definition for the painful bladder syndrome (PBS), a concept embraced by many IC investigators, some of whom have used the name IC/PBS. In a study of recent onset IC/ PBS patients, we had two objectives: to determine 1) what proportion met the ICS definition and 2) how did those who met the definition differ from those who did not.Methods-Having recruited women who had recent onset IC/PBS for an ongoing case control study to identify its risk factors, we studied our first 138 eligible cases to identify those who met the ICS definition. We then compared those who met the definition to those who did not by variables acquired through interviews and medical records. The most liberal interpretation of the ICS definition did not include 47/138 (34%) of our cases. Comparing these to the 91 (66%) who did meet the ICS criteria, we found that 96/97 clinical variables, including many generally thought characteristic of IC/PBS, were not significantly different between the 2 groups. Results-The

show abstract

“…[6] Information on the relationship between analgesic use and end-stage renal disease. [7,8] Information on the effects of treatment with beta-cell antigens on the onset of Type 1 Diabetes Mellitus.…”

Section: Datasetsmentioning

confidence: 99%

NIDDK data repository: a central collection of clinical trial data

Cuticchia

Cooley

Hall

et al. 2006

BMC Med Inform Decis Mak

View full text Add to dashboard Cite

show abstract

The interstitial cystitis data base study: Concepts and preliminary baseline descriptive statistics

Cited by 236 publications

References 11 publications

A prospective, single‐blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis

A prospective, single‐blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis

Using the International Continence Society’s definition of painful bladder syndrome

NIDDK data repository: a central collection of clinical trial data

Contact Info

Product

Resources

About